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RIG-I is a key innate immune pattern-recognition
receptor that triggers interferon expression upon
detection of intracellular 50triphosphate double-
stranded RNA (50ppp-dsRNA) of viral origin. RIG-I
comprises N-terminal caspase activation and re-
cruitment domains (CARDs), a DECH helicase, and
a C-terminal domain (CTD). We present crystal struc-
tures of the ligand-free, autorepressed, and RNA-
bound, activated states of RIG-I. Inactive RIG-I has
an open conformation with the CARDs sequestered
by a helical domain inserted between the two heli-
case moieties. ATP and dsRNA binding induce a
major rearrangement to a closed conformation in
which the helicase and CTD bind the blunt end
50ppp-dsRNA with perfect complementarity but in-
compatibly with continued CARD binding. We pro-
pose that after initial binding of 50ppp-dsRNA to the
flexibly linked CTD, co-operative tight binding of
ATP and RNA to the helicase domain liberates the
CARDs for downstream signaling. These findings
significantly advance our molecular understanding
of the activation of innate immune signaling heli-
cases.INTRODUCTION
RIG-I-like helicases (RLHs), which include RIG-I (retinoic acid-
inducible gene I, DDX58), MDA-5 (melanoma differentiation-
associated gene 5), and LGP2 (DHX58), are key cytosolic
pattern-recognition receptors (PRRs) of the vertebrate innate
immune system that form the first line of defense against infec-
tion by RNA viruses (Yoneyama et al., 2004). PRRs are sensors
of nonself microbe-associated molecular patterns (MAMPS),
which in the case of RLHs are virus-specific RNA structures.
Detection of viral RNA MAMPS by RIG-I activates the NF-kB
and IRF3 signaling pathways, leading to interferon-b (IFN-b)production. This in turn leads to the upregulation of numerous
IFN-stimulated genes (ISGs), including RIG-I itself, that either
directly combat the viral infection or mobilize other cells of the
immune system (Gerlier and Lyles, 2011). RIG-I is activated by
diverse positive- and negative-stranded RNA viruses including
influenza, rift valley, measles, vesicular stomatitis (VSV), and
hepatitis C viruses (Loo and Gale, 2011). Mice deficient in RIG-I
are more susceptible to infection by RNA viruses (Kato et al.,
2006), and the natural RIG-I deficiency of chickens may con-
tribute to their high susceptibility to influenza virus (Barber
et al., 2010; Karpala et al., 2011).
RIG-I, a 925 residue, 106 kDa protein in human (hRIG-I),
is highly conserved within vertebrates and comprises two
N-terminal tandem caspase activation and recruitment domains
(CARDs), a central DECH-box RNA helicase, and a C-terminal
domain (CTD). MDA-5 has a similar architecture, whereas
LGP2 lacks the CARDs. The RLHs form a subgroup of super-
family 2 (SF2) RNA helicases and are closely related to DEAD-
box helicases (Fairman-Williams et al., 2010). They comprise
N- and C-terminal RecA-like domains (denoted Hel1 and Hel2)
that contain up to 12 conserved sequence motifs involved in
nucleic acid and ATP binding and in ATP hydrolysis (Linder
and Jankowsky, 2011). RIG-I is thus a double-stranded RNA
(dsRNA)-dependent ATPase (Gee et al., 2008). The RIG-I sub-
family includes Dicer, involved in the processing of small
RNAs, as well as archaebacterial helicase-associated endonu-
clease for fork-structured DNA (Hef) (Nishino et al., 2005) and
its vertebrate orthologs (Mosedale et al., 2005). In uninfected
cells, RIG-I is thought to be in an autorepressed conformation,
with the CARDs unavailable for signal transduction. In vitro
activation of RIG-I requires either an RNA that forms a blunt-
ended, base-paired region of at least 18–20 nucleotides with a
50triphosphate and free of mismatches near the blunt end
(denoted 50ppp-dsRNA [50triphosphate double-stranded RNA])
(Marq et al., 2010; Schlee et al., 2009; Schmidt et al., 2009) or
much longer (>200 bp) dsRNAs, including poly(I:C), not neces-
sarily bearing a 50ppp-end (Binder et al., 2011; Kato et al.,
2008). However, the nature and origin of the RNA species rele-
vant for RIG-I activation in virally infected cells are unclear.
Panhandle structures, which occur in many RNA virus systems
and correspond to the blunt-end 50ppp-dsRNA RIG-I MAMPCell 147, 423–435, October 14, 2011 ª2011 Elsevier Inc. 423
(Schlee et al., 2009), have been implicated, for instance, associ-
ated with viral genomic RNA or defective interfering particles in,
respectively, influenza- or Sendai-infected cells (Baum et al.,
2010; Rehwinkel et al., 2010; Stra¨hle et al., 2007). RNA binding
to RIG-I is mediated both by the CTD, which specifically binds
the 50triphosphate end, and by the helicase domain. The CTD,
which contains a structural zinc ion, binds blunt-end 50ppp-
dsRNA with a 10-fold higher affinity compared to 50OH-dsRNA
(Cui et al., 2008; Hornung et al., 2006; Lu et al., 2010; Pichlmair
et al., 2006; Takahasi et al., 2008; Wang et al., 2010). Viral RNA
binding to RIG-I is thought to induce conformational changes
that expose the CARDs, allowing E3-ligase tripartite motif-
containing 25 (TRIM25)-dependent K63 polyubiquitination of
Lys172 (Gack et al., 2007) or endogenous K63-linked polyubiqui-
tin chain binding (Zeng et al., 2010). The polyubiquitinated
CARDs then recruit the adaptor MAVS (mitochondrial antiviral
signaling protein, also known as IPS-1/CARDIF/VISA) via CARD-
CARD interactions (Kawai et al., 2005; Meylan et al., 2005;
Seth et al., 2005; Xu et al., 2005). Upon activation, MAVS aggre-
gates in the outermitochondrialmembrane (Houet al., 2011;Ono-
guchi et al., 2010) and, via a complex set of adapters and kinases
(Belgnaoui et al., 2011), activates the transcription factors IRF3,
IRF7, AP1, and NF-kB that co-operatively coordinate the expres-
sion of type I IFN genes (Honda and Taniguchi, 2006). Several
additional protein-modifying enzymes and RNA-binding en-
hancers have been proposed to modulate the function of RIG-I
(Wilkins and Gale, 2010; Yoneyama and Fujita, 2010). Many
RNA viruses have evolved mechanisms to counteract the RLH
pathway (Bowie and Unterholzner, 2008), including direct inhibi-
tion of RIG-I by Z protein of new world arenaviruses (Fan et al.,
2010), modulation of TRIM25-mediated polyubiquitination of
RIG-I by NS1 of some influenza viruses (Gack et al., 2009; Kuo
et al., 2010), and inactivation by cleavage of MAVS by HCV
protease (Li et al., 2005).
Several mechanistic questions concerning the RIG-I activation
pathway remain open, including the nature of the conformational
changes and oligomerization state associated with viral RNA
binding and the respective roles of ATP binding and hydrolysis.
To resolve these issues, detailed structural information on the
different states of RIG-I is essential. Although the crystal struc-
ture of RIG-I CTD bound to short 50ppp-dsRNA has been deter-
mined (Lu et al., 2010;Wang et al., 2010), neither the overall RIG-I
architecture nor the atomic structure of any other domain, with or
without bound RNA, is known. As our attempts to crystallize
hRIG-I were unsuccessful, we turned to the homolog from the
mallard duck Anas platyrhynchos (dRIG-I), which shares 53%
sequence identity with hRIG-I (Data S1 available online). Trans-
fection of dRIG-I into chicken cells (which naturally lack RIG-I
or a RIG-I-like activity) (Karpala et al., 2011) enables them to
respond to 50ppp-RNA and activate interferon gene expression
(Barber et al., 2010). dRIG-I has in vitro dsRNA-dependent
ATPase activity (Figure S1A) and was also found to elicit an anti-
viral state in chicken DF-1 cells in response to a 50ppp leader
RNA transcript from rabies virus (Figure S1B), indicating a likely
similarity of the mechanisms of action of dRIG-I and hRIG-I. We
crystallized and determined the structure of the following
constructs of dRIG-I: the helicase domain alone (dRIG-I-Hel,
242–794) and in ternary complex with an ATP analog and an424 Cell 147, 423–435, October 14, 2011 ª2011 Elsevier Inc.unphosphorylated 19-mer dsRNA (dRIG-I-Hel-ds19), dRIG-I-
DCTD (1–794), and full-length dRIG-I (dRIG-I-FL, 1–933). These
structures, together with previously published data, enable us
to propose a detailed structure-based mechanism for RIG-I acti-
vation by viral RNA.
RESULTS AND DISCUSSION
Structure of Ligand-free RIG-I Helicase Domain
The dRIG-I-Hel structure was determined at 3 A˚ resolution by the
single anomalous diffraction method using seleno-methionine-
labeled protein (Figure S2A). Ligand-free RIG-I helicase shows
an open conformation in which the Hel1 (242–456) and Hel2
(458–469, 609–745) domains are not in direct contact, and
several interstrand loops, particularly of Hel2, are disordered
(Figure 1). Secondary structure elements and helicase motifs
are indicated in the RIG-I sequence alignment in Data S1. The
C-terminal extension of Hel1 links to the outermost strand (b8)
of Hel2 and then directly into an insertion domain (denoted
Hel2i, residues 470–608), which is a bundle of five long, antipar-
allel a helices (a22–a26) (Figure 1C). Hef, themember of the RIG-I
subfamily of helicases with the highest sequence homology to
RLHs, has the same overall architecture as RIG-I (Figure 1D).
Themost striking feature of RIG-I helicase is an elbow-like helical
structure that emerges from Hel2 and that will be referred to as
the bridging domain (also named the pincer domain; see accom-
panying article by Luo et al. [2011; this issue of Cell]). This
comprises a long a helix (a31, 746–769) that bridges back to
Hel1, with an 80 bend at conserved residue Trp772 leading
into a second helix (a32, 774–793), which would connect to the
CTD, absent from this construct (Figure 1). Extensive contacts
are made by residues 761–789, either side of the bend, with resi-
dues on helices a19 and a20 and the following linker of Hel1. The
proximal end of a31 has counterparts in other helicases (e.g.,
Hef, Figure 1D, and DPB5; see below), but the elbow structure
bridging to the Hel1 domain is specific to RIG-I. Hel1-interacting
residues E759, M762, Q770, K780, and Q785, some of which
stabilize elements of the ATP-binding site (see below), are highly
conserved, suggesting that the bridging domain is common to all
RLH family members (Data S2).
Structures of the helicase in the context of the longer
constructs dRIG-I-DCTD (1–794) and full-length dRIG-I (1–933)
were also determined (see below). In all ligand-free structures,
the helicase is in an open conformation with Hel2 and Hel2i form-
ing a single rigid-body unit (Hel2i-Hel2 module). Between the five
crystallographically different RIG-I molecules in three crystal
forms, there is an angular span of about 30 in the orientation
of theHel1 domain after superposing theHel2i-Hel2module (Fig-
ure 1E; Movie S1). The two hinge regions lie between residues
456 and 460 in the linker between Hel1 and b8 of Hel2 and
744–748 preceding the bridging helix a31. This highlights the
intrinsic flexibility of the open form of the helicase, which prob-
ably contributes to the difficulty in crystallizing RIG-I.
Structure of dRIG-I Helicase Bound to a 19-mer dsRNA
and ATP Analog
Full-length RIG-I shows optimal RNA-dependent ATPase activity
in the presence of 50ppp-dsRNA, whereas RIG-I lacking the
A
HEL1 HEL2i HEL2
458 470 608 744 497242
Hel1α32
Hel1
α32
α21 α18
α19
α20
α14
Hel1Bridging
domain
794
Hel2i
Hel2
α31
α20
α31
α23
β8
α16
Bridging
domain
Hel2
487
Hel2i
Hel2
B C D
α8
α26
α24
α22
α25
Hel2i
α27
49°
Hel1
28° Hel1
19-mer
dsRNA
3′5′Hel2
24° Hel2i
FE
Hel2i
Figure 1. Structure of dRIG-I Helicase
Domain
(A) Domain structure of dRIG-I helicase. Colors
are Hel1 (green), Hel2i (yellow), Hel2 (cyan), and
bridging domain (red). Residues at domain
boundaries are numbered.
(B and C) Two orientations of dRIG-I helicase in
surface and/or ribbon representation. Colors are
as in (A), and key secondary structure elements
are labeled.
(D) Ribbon representation of Pyroccoccus furiosus
Hef (PDB 1WP9) showing similar architecture as
dRIG-I. The individual subdomains Hel1, Hel2, and
Hel2i of Hef superpose on those of RIG-I with
rmsds on Ca positions of 1.36 A˚ (153 matched,
33% identical), 1.15 A˚ (68 matched, 28% iden-
tical), and 1.51 A˚ (64 matched, 11% identical),
respectively, although their relative orientation is
different. Colors as in (A).
(E) Flexibility of the dRIG-I helicase domain.
Superposition based on the Hel2-Hel2i module
of five crystallographically independent molecules
of ligand-free dRIG-I helicase, showing relative
angular movement of Hel1 spanning 28. Colors:
1–794 chain D (cyan), 1–933 chain B (green), 242–
794 (orange), 1–933 chain A (magenta), 1–794
chain A (red). See also Movie S1.
(F) Conformational change of the dRIG-I helicase
domain upon ligand binding. The open state is
in orange (1–933, chain A), and the closed state
arising from simultaneous dsRNA (red and purple
strands) and ADP-AlF3-Mg
++ (not shown) binding
is in black. Superposing on the Hel2 domain, the
Hel1 domain rotates by 49 and Hel2i by 24.
See also Data S1, Figures S1 and S2, and
Movie S2.tandem CARDs (RIG-I-DCARDs) is equally active with 50ppp- or
50OH-dsRNA (Cui et al., 2008). Additionally, removing the
CTD (i.e., RIG-I-Hel) significantly reduces ATPase activity (Cui
et al., 2008), possibly due to reducedoverall RNA-binding affinity.
We succeeded in crystallizing dRIG-I-Hel with a blunt-ended
50OH-dsRNA 19-mer in the presence of either the nonhydrolyz-
able ATP analog AMPPNP (monoclinic form, 4.2 A˚ resolution)
or the transition state analog ADP-AlF3 (tetragonal form, 3.7 A˚
resolution) (Figure 2B). Despite the modest resolution, the struc-
ture is well defined, with clear electron density for the ADP-AlF3-
Mg++ (Figure S2B) and the RNA (Figure S2C). In both crystal
forms, the dsRNA forms pseudocontinuous A-form double
helices throughout the crystal but with dislocations in the back-
bone between the 19-mers (Figures 2C and S2C). In the tetrag-
onal form, crystallographically independent RIG-I molecules
alternate along this pseudohelix without contacting each other,
with an average spacing of 53 A˚ (Figure 2C). In the monoclinic
crystal, the two independent RIG-I molecules form two distinct,
parallel pseudocontinuous helices (not shown).Cell 147, 423–435,Co-operative dsRNA and ATP bind-
ing results in a dramatic conformational
change of the RIG-I helicase with all three
subdomains (Hel1, Hel2i, and Hel2) mov-
ing relative to each other (Figure 1F;Movie S2). This brings the two RecA domains into intimate
contact, creating themature dsRNA- and ATP-binding sites (Fig-
ure 2). UsingHel2 as reference, theHel1 domain rotates by about
60 from its extreme position in the free helicase structures, and
the Hel2i domain rotates 23 to form one wall of the dsRNA-
binding groove. The configuration of Hel1, Hel2, and RNA thus
becomes very similar to that observed for other RNA helicases
bound to ATP and single-stranded RNA (ssRNA) (e.g., DPB5,
Figure 2D). Almost all the previously disordered loops from
both RecA domains are now well defined and take part in RNA
or ATP binding, in accordance with the canonical functions of
the various conserved helicase motifs (Linder and Jankowsky,
2011). Direct ADP-AlF3-Mg
++ binding involves residues from
motif Q (Lys245 and Gln250 define the adenine specificity,
Arg247 stacks on the adenine base), motif I (Walker A, 270–
GxGKT), motif Ia (308–QQ), motif II (Walker B, 375–DE), motif
Va (Gly704, Asp706-ribose), and motif VI (Gln727, Arg731,
Arg733) (Figure 2E). As mentioned above, certain residues of
the bridging helix a31, highly conserved in all RLH familyOctober 14, 2011 ª2011 Elsevier Inc. 425
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Figure 2. Structure of the dRIG-I Helicase
Domain in Complex with 19-mer dsRNA
and ADP-AlF3-Mg
++
(A) Sequence of 19-mer dsRNA with 50 strand in
red and 30 strand in purple. Triangles mark protein
contacts to the RNA backbone via residues in the
helicase motifs indicated. Nucleotides are num-
bered according to the convention used through-
out the text.
(B)Ribbon representationof thedRIG-Ihelicase:19-
mer dsRNA:ADP-AlF3-Mg
++ complex. Colors as in
Figures 1A and 2A. The ADP-AlF3-Mg
++ is shown
with spheres.
(C) Crystal packing of the dRIG-I helicase:19-mer
dsRNA:ADP-AlF3-Mg
++ complex. The two inde-
pendent complexes in the asymmetric unit are in
cyan/magenta and green/yellow for the protein/
RNA. The 19-mer dsRNA molecules form a zig-
zag pseudocontinuous helix with dislocations.
(D) Structural comparison of dsRNA binding to
RIG-I (left) and ssRNA binding to Dpb5/DDX19
(right). The combined Hel1 and Hel2 domains
were superposed (DALI z score = 30.8, rmsd 2.6 A˚
for 308 Ca positions aligned). Dbp5/DDX19 is
involved in mRNA export (PDB entry 3PEY). The
dispositions of the two helicase domains (re-
spectively, green and cyan), ATP-binding site, and
the 30 strand (purple) bindingmode are very similar
for the two helicases.
(E) ADP-AlF3-Mg
++-binding site showing disposi-
tion of key residues in the conserved ATP-binding
helicase motifs. Colors: motif Q (pink), I (green), II
(magenta), III (gray), Va (orange), and VI (cyan).
Motifs are defined in Data S1. Two conserved
residues from the bridging helix a31 (red), which
stabilize motifs III and VI, are also shown. In other
helicases, such as Dpb5, analogous stabilization
of motif VI occurs with residues from a C-terminal
helix equivalent to the proximal part of the bridg-
ing helix a31, but motif III is stabilized by Hel1
elements, which take the same position as the
distal end of the helix a31 in RIG-I. The corre-
sponding Hel1 element in RIG-I (residues 442–
456, i.e., b7 and a21) is consequently displaced.
See also Data S1 and Figures S2 and S3.members, are involved in stabilizing ATP-binding elements, e.g.,
Met762 interacts directly with motif III residues 414–VG, close to
the site of ATP hydrolysis (Banroques et al., 2010), and E759
makes a salt bridge to residue R729 (conserved across the
RLH family) in ATP-binding motif VI (Figure 2E).
A significant observation is that in all four crystallographically
independent complexes (two in each crystal form), RIG-I heli-
case binds at one blunt-end extremity of the 19-mer dsRNA (Fig-
ure 2C). Denoting 50-GCAUGCGACCUCUGUUUGA as the 50
strand (with individual positions denoted 1, 2, 3..) and its comple-
ment, 30-CGUACGCUGGAGACAAACU, as the 30 strand (with
individual positions denoted 1*, 2*, 3*..) (Figure 2A), the 30 strand
backbonemakes themost contacts with the helicase (Figures 2A
and 2D). The backbone of the 30 extremity of the 30 strand (nucle-
otide 1*, Figure 2A) is bound in a pocket involving interactions of
Gly329 main-chain amide (motif Ib) and Thr350 (motif Ic) with the426 Cell 147, 423–435, October 14, 2011 ª2011 Elsevier Inc.phosphate and Asn356 with the ribose. In the crystal structure,
a second 19-mer is stacked against the 1*:1 blunt end, but the
first base of this adjacent dsRNA (equivalent to 19*) is stacked
over the center of the 1*:1 base pair, and there is a clear disloca-
tion in the continuity of the backbone (Figures 2C and S2C). This
suggests that the helicase preferentially binds a 30 end at this
site. Phosphates 2*–4* of the 30 strand are bound via canonical
motifs as observed in several ssRNA-binding helicases (e.g.,
DPB5, Figure 2D) (Linder and Jankowsky, 2011) and frequently
involve main-chain amide interactions. The phosphate of nucle-
otide 2* binds the main-chain amide of Val303 (motif Ia; mutation
of the preceding residue in hRIG-I eliminates RNA binding) (Plu-
met et al., 2007), that of 3* binds the main-chain amide of Thr698
(motif V; mutation of this conserved residue to alanine in hRIG-I
eliminates dsRNA binding) (Bamming and Horvath, 2009), the
side chain of Arg638, and the main-chain amide of Gly663, and
that of 4* binds the main-chain amide and side chain of Arg638
(motif IV). However, the following interactions, to both RNA
strands, are unique to RIG-I and likely explain its preference for
dsRNA. 30 strand nucleotides 6*, 7*, and 8* interact with Hel2i
domain residues Glu511, His512, Val515, and Arg519 on helix
a23. The 50 strand is recognized through contacts involving the
backbones of nucleotides 4, 5, 8, and 9. Beyond nucleotides
8* and 9, neither strand makes any further contact with the
RIG-I helicase. A particularly important interaction is that of
the phosphate of nucleotide 5 with the main-chain amide of
Asn383, immediately following the ATP-binding motif II (Walker
B, 375–DECH). This asparagine is part of motif 383-NHPYNVIM
and corresponds to 183-DHPYREIM in human Dicer (bold resi-
dues are highly conserved), suggesting that this is a conserved
structural motif for binding a 50 chain phosphate in this subfamily
of double-stranded nucleic acid-binding helicases (designated
motif IIa in Figure 2A and Data S1). A functionally equivalent motif
exists in SWI2/SNF2 ATPases that bind dsDNA (Du¨rr et al.,
2005). 50 strand nucleotides 8 and 9 interact with Gln508 and
Asn509 on helix a23 of theHel2i domain. Note thatmost residues
on helix a23 cited above (Gln508, Glu511, His512, Val515, and
Arg519) are highly conserved or conservatively substituted in
all known RIG-I sequences (Data S1). This region of Hel2i also
interacts with the CARD2 in the RNA-free dRIG-I structures
described below.
The crystal structure shows that the footprint of the RIG-I heli-
case domain on dsRNA is 9–10 bp. This, together with the
apparent preference for 30 end dsRNA binding, even in the
absence of the CTD, explains why the 19-mers used in crystalli-
zation only bind one RIG-I molecule at one end. Perhaps coinci-
dentally, the arrangement of complexes in the crystal mimics
the reported average density of 10–15 RIG-I molecules bound
per 200 bp on long dsRNA (i.e., 35–52 A˚ apart) (Binder et al.,
2011). However, in neither crystal form do the RNA-bound
RIG-I molecules dimerize through protein-protein interactions.
Thus RNA binding per se does not induce multimerization of
RIG-I. These observations are consistent with biophysical results
showing that ligand-free dRIG-I and hRIG-I are both monomeric,
and that binding a short (20 bp) 50ppp-dsRNA gives a 1:1
complex whereas binding to longer (60 bp) 50ppp-dsRNA
results in an RNA-mediated 2:1 complex through binding of
one RIG-I molecule to each end (Figure S3).
The Structure and Intramolecular Interactions
of the Tandem CARDs of RIG-I
The crystal structures of ligand-free RIG-I-DCTD (1–794) and full-
length dRIG-I-FL (1–933) reveal the structure and position of the
tandem CARDs of RIG-I in the ligand-free state (Figures 3A
and 3B). Despite the moderate resolution, the electron density
for the CARDs is good enough to fit side chains with confidence,
aided by the seleno-methionine positions derived from anoma-
lous difference data (Figure S4A). The structure of the tandem
CARDs, an unusual duplication of a common signaling domain
that occurs only in RIG-I, MDA-5, and NOD2, another cytosolic
innate immune receptor (Fritz et al., 2006), is shown in Figure 3C.
Both domains (denoted CARD1 and CARD2) have the canonical
CARD fold and superimpose with a root-mean-square deviation
(rmsd) of 1.35 A˚ for 87 matched residues (15% identical). TheC terminus of CARD1 links directly to the extended N-terminal
helix (a8) of CARD2 (Figure 3C). The two CARDs thus form
a head-to-tail unit, the transformation from the first to the second
involving a rotation of 46. There is intimate contact between the
top (head) of CARD1 and the bottom (tail) of the CARD2, in-
volving both hydrophobic and polar interactions. The CARD1-
CARD2 interface is mediated by residues highly conserved in
all RIG-Is, notably Tyr24, Tyr81, Ile130, and the peptide 159-
RSDK (Data S1; Figure S4B). The structure strongly suggests
that the tandem CARDs form an essentially rigid functional
unit, consistent with the fact that only the intact double domain
is capable of signaling (Zeng et al., 2010).
In all four crystallographically independent molecules in the
RIG-I-DCTD structure and the two in the RIG-I-FL structure,
the tandem CARDs are identically bound to the insertion domain
(Hel2i) of the helicase (Figures 3B and 3D). Although the 55
residue linker between CARD2 and Hel1 is invisible in the elec-
tron density due to disorder, the monomeric state of free RIG-I
(Figure S3) indicates that the CARDs most likely bind to the
Hel2i domain of the same molecule, rather than being swapped
between monomers. Three segments (residues 106–114, 143–
150, and 176–185) at the top end of CARD2 interface with helices
a23, a24, and a25 of Hel2i, burying a substantial solvent-
exposed surface totaling 1971 A˚2 (Figure S4C). The interface in-
cludes a number of putative salt bridges (e.g., Arg537-Glu110,
Lys548-Glu115, Arg519-Glu183, Arg522-Asp186) as well as
significant hydrophobic contacts. Most of the implicated resi-
dues are conserved or conservatively substituted in all RIG-Is,
e.g., the key hydrophobic interactions are made by Ile109 and
Leu184 in the CARDs and Phe540 and Phe571 in Hel2i (equiva-
lent residues in hRIG-I: Leu110, Leu185, Phe539, and Phe570)
(Data S1; Figure S4C). CARD2’s extensive contact with the
Hel2i domain, its proximity to the Hel1 domain, and possibly
the excluded volume of the CARD2-Hel1 linker would sterically
hinder its interactions with other macromolecules, notably K63-
linked polyubiquitin or the ubiquitin ligasemachinery. In contrast,
the CARD1 surface, apart from that binding CARD2, is solvent
accessible (Figure 3D).
Full-length dRIG-I (1–933) crystallizes in a different space
group than RIG-I-DCTD (1–794), yet the determined structures
are very similar due to the absence of any electron density for
the additional CTD in the full-length crystals. However, the last
bridging helix visible (a32) leads into an ‘‘empty’’ crystal volume
that could accommodate the CTD. The presence of the zinc-
containing CTD in the crystals is confirmed by a clear zinc
absorption edge signal, and gel analysis of crystals shows full-
length protein (data not shown). This suggests that in the RNA-
free state, the CTD is flexibly linked to the rest of the protein
and has no strong interaction with it, as confirmed by pull-
down experiments with purified CTD.
Implications for the Functions of the Tandem CARDs
In the current model of hRIG-I activation, the tandem CARDs are
proposed to play an important role in autorepression and sig-
naling (Gack et al., 2008; Meylan et al., 2005; Saito et al., 2007;
Zeng et al., 2010). Intact tandem CARDs (minimally residues
1–190) (Zeng et al., 2010) are necessary and sufficient for sig-
naling, whereas RIG-I-DCARDs (Saito et al., 2007) and a humanCell 147, 423–435, October 14, 2011 ª2011 Elsevier Inc. 427
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Figure 3. Structure of dRIG-I DCTD and the
Tandem CARDs
(A) Domain structure of dRIG-I DCTD con-
struct. Colors are CARD1 (light magenta), CARD2
(blue), Hel1 (green), Hel2i (yellow), Hel2 (cyan), and
bridging domain (red).
(B) Ribbon diagram of dRIG-I DCTD structure.
Colors as in (A).
(C) Ribbon diagram of tandem CARDs. Colors as
in (A), except that the linker between CARD1 and
CARD2 is in straw. CARD1 (residues 1–91) and
CARD2 (residues 100–186) are structurally most
similar to, respectively, the CARD of APAF1 (PDB
1CY5, Dali z score = 14.9, 21% identical) and the
CARD of MAVS (PDB 2VGQ, Dali z score = 13.3,
17% identical). The positions of some functionally
important residues in the CARDs that are dis-
cussed in the text are shown in orange: Ser8
(conserved in hRIG-I), Ala55 (T55 in hRIG-I), and
Gln170 (Lys172 in hRIG-I).
(D) Orthogonal surface diagrams of the dRIG-I
DCTD structure showing tandem CARDs with
CARD2 (blue) forming a large interface with Hel2i
(yellow). In the right-hand diagram, the residues
186 (end of CARD2) and 245 (beginning of Hel1),
which are spatially separated by 42 A˚, are indi-
cated in black. The 58 residue linker connecting
these residues, disordered in the crystal structure,
is represented by a dotted black oval.
See also Figure S4.splice variant with residues 36–80 deleted from CARD1 (Gack
et al., 2008) are dominant negative. Upon RIG-I binding to an
RNA agonist, CARD1 is thought to become available for interac-
tion with the E3 ubiquitin ligase TRIM25 via its PRYSPRY domain
(Gack et al., 2007). This interaction is inhibited by the mutation
Thr55Ile (Gack et al., 2008), which confers permissivity to hepa-
titis C virus infection by blocking RIG-I signaling (Sumpter et al.,
2005). Binding of TRIM25 leads to K63-linked polyubiquitination
of Lys172 on CARD2 (Gack et al., 2007), a covalent modification
that enhances the CARD-CARD interaction of RIG-I with the
downstream adaptor protein MAVS (Gack et al., 2008). In an
alternative scenario, downstream signaling via MAVS requires
the binding of unanchored K63-linked polyubiquitin chains
generated by TRIM25 to the hRIG-I CARDs, the binding impli-
cating the same residues Thr55 and Lys172 (Hou et al., 2011;
Zeng et al., 2010). Yet other authors have questioned the impor-
tance of Lys172 for RIG-I signaling (Shigemoto et al., 2009). For428 Cell 147, 423–435, October 14, 2011 ª2011 Elsevier Inc.dRIG-I, it is unknown whether signaling is
polyubiquitin dependent or not. In birds
and mouse, Lys172 is substituted by a
glutamine (Gln170 in dRIG-I, Data S1),
which clearly cannot be covalently polyu-
biquitinated, but this may not be re-
levant if only polyubiquitin binding is
necessary. In any case, due to the high
sequence conservation among RIG-Is,
the dRIG-I tandem CARDs likely repre-
sent the equivalent hRIG-I structure well
enough to interpret published results onhRIG-I. The side chain of Gln170 (Lys172 in hRIG-I) is close
and possibly interacting with the C-terminal extremity of
CARD2 (residue 186, before the 55 residue long, flexible linker
to the helicase domain) (Figures 3C and 3D) and is also very close
to CARD2’s interface with Hel2i. Thus, in the inactive conforma-
tion, there is probably significant steric hindrance to poly-
ubiquitination or polyubiquitin binding at this site, due to either
the large size of the polyubiquitination machinery (Gack et al.,
2009) or the space required by the flexible linear K63-linked pol-
yubiquitin chains (Datta et al., 2009). Thr55 in hRIG-I, thought to
interact with the TRIM25 PRYSPRY domain, corresponds to
Ala54 in dRIG-I, which is a solvent-exposed residue on helix a8
in the center of one face of CARD1 (Figure 3C). However, little
is known about the mode of interaction of hRIG-I CARDS with
either the TRIM25 PRYSPRY domain or the CARD of MAVS.
The latter interaction may involve multiple CARDs from several
RIG-I and MAVS molecules, as observed in other death-domain
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Figure 4. Structural Models of the Autore-
pressed andActivated 50ppp-dsRNA-Bound
States of dRIG-I
(A) Domain structure of full-length dRIG-I. Colors
are CARD1 (light magenta), CARD2 (blue), Hel1
(green), Hel2i (yellow), Hel2 (cyan), bridging do-
main (red), and CTD (orange).
(B) Model of the dRIG-I helicase + CTD bound to
50ppp-dsRNA. The model was constructed by
superposing, via only the A-form dsRNA, the
structure of dRIG-I CTD:14-mer 50OH-dsRNA (or-
ange) on dRIG-I helicase:19-mer dsRNA. A similar
result is obtained using the hRIG-I CTD 50ppp-
dsRNAstructure (PDBentry 3NCU). The reddotted
line represents the missing link between the end
of the bridging domain (793) and the start of the
CTD (807).
(C) Diagram showing the complementarity of
binding of the CTD and helicase to 50ppp-dsRNA.
(D) Same model as in (B) but orthogonal view and
with ADP-AlF3-Mg
++ visible. The protein encircles
the dsRNA.
(E) As in (D) but with surface added for the pro-
tein. There are only minor clashes between the
modeled position of the CTD and the rest of the
structure.
(F) Comparison of autorepressed dRIG-I and
model of 50ppp-dsRNA-activated state. Left:
Crystal structure of the autorepressed dRIG-I with
the flexibly linked CTD (orange, dotted) connected
to the end of the bridging domain. Right: Model of
50ppp-dsRNA-activated state aligned with the
structure of the autorepressed state by superpo-
sition on Hel2i (yellow). CARD2 (blue) binding to
Hel2i is incompatible with the positions of the
dsRNA (crystal structure) and CTD (modeled). The
flexibly linked CARDs are shown dotted (blue and
light magenta).
See also Figure S5.complexes (Kersse et al., 2011; Lin et al., 2010), as well as
K63-linked polyubiquitin. Finally, it has been reported that the
phosphorylation of Ser8 residue negatively regulates hRIG-I
apparently by preventing TRIM25 binding (Gack et al., 2010;
Nistal-Villa´n et al., 2010). Ser8 is conserved in dRIG-I where it
is solvent exposed (Figure 3C) and thus accessible to a kinase
that may possibly stabilize the autorepression state of RIG-I.
Structural Model for 50ppp-dsRNA Binding to the
Helicase and CTD
The apparent preferential binding of dRIG-I helicase to the 30 end
of a short dsRNA led us to ask whether this was structurally
compatible with the known mode of binding of a blunt-end
50ppp-dsRNA to the CTD of RIG-I. First we solved the structures
of the dRIG-I CTD alone (residues 806–933, 1.44 A˚ resolution)
and in complex with a 14-mer blunt-end 50OH-dsRNA (4 A˚ reso-
lution). As expected, these structures are very similar to the cor-
responding published hRIG-I CTD structures (Lu et al., 2010;Cell 147, 423–435,Wang et al., 2010) and confirm that for
dRIG-I, the loop 849–857 changes con-
formation upon dsRNA binding, allowingPhe855 to stack on the blunt-end bases (Figure S5). We then
superposed the blunt-end dsRNA from the dRIG-I CTD-dsRNA
complex on that of the helicase-dsRNA complex, as both are
essentially regular A-formRNA. Remarkably, after superposition,
there is no significant clash between the CTD and the helicase
(Figure 4B), and the protein encircles and caps the blunt-end
dsRNA extremity (Figures 4D and 4E). Most significantly, there
is perfect complementarity between the binding modes of the
helicase and CTD to the blunt-end dsRNA. Whereas the helicase
interacts mainly with the 30 strand, the CTD interacts mainly with
the 50 extremity, including the triphosphate (Lu et al., 2010;Wang
et al., 2010) (Figure 4C). The pattern of recognition suggests
that RIG-I would be less tolerant of mismatches perturbing
the canonical A-form backbone conformation within the first
4–5 bp from the blunt end, as reported (Schlee et al., 2009).
Furthermore, the observed end of the helicase domain (residue
793) and the beginning of the CTD (residue 807) are both on
the same side of the molecule and orientated toward each otherOctober 14, 2011 ª2011 Elsevier Inc. 429
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Figure 5. Functional Validation of the
CARD-Mediated Repressor Model
(A) Interdomain interactions in the dRIG-I mole-
cule. 5 mM RIG-I helicase or 5 mM RIG-I DCTD
were incubated with 4 mM his-tagged CARDs (1–
210) and 4 mM his-tagged CTD (806–933),
respectively, in 20 mM HEPES (pH 8), 20 mM
NaCl. After incubation with Ni-NTA and washing
with the same buffer containing 50 mM imidazole,
the complexes were eluted with the buffer con-
taining 300 mM imidazole. Fractions were ana-
lyzed on denaturing SDS-PAGE. The helicase
domain coelutes with the CARDs alone (lane 6),
but addition of 5 mM 19-mer dsRNA weakens the
interaction (lane 8). The CTD forms a complex
neither with the helicase domain alone (lane 10)
nor with RIG-I DCTD (lane 18). The CARDs in cis of
RIG-I DCTD (1–794) prevent the helicase binding
in trans with the CARDs (lane 16).
(B–F) Mutation of Phe540 and Phe539 results in
dRIG-I and hRIG-I being constitutively active in
chicken and/or human cells
(B) Expression of wild-type (WT) and mutant
dRIG-I and hRIG-I in chicken DF-1 and human
Huh7.5 cells.
(C) Expression of dRIG-I in chicken DF-1 cells
activates the IFN response as shown by the sig-
nificant increase in Mx1 gene activation over the
empty vector. F540A and F540D mutants exhibit
an 4 fold higher activity than WT dRIG-I, despite
being less expressed (B).
(D) Expression of both hRIG-I (blue) and dRIG-I
(red) in human cells activates the human IFN-b
promoter (4- to 5-fold) in human Huh7.5 cells,
but only hRIG-I gets strongly activated by the
rabies leader 50ppp-RNA (10-fold). F539A and
F539D induce a significantly higher (4- to 6.5-fold) stimulation than WT hRIG-I, as do F540A and F540D when compared to WT dRIG-I (1.6- to
2.1-fold).
(E) Plasmid titrations of parental and mutant RIG-I further confirmed the constitutive activity of the latter. The activity of dRIG-I F540A/D mutants is
remarkable in human cells, as parental dRIG-I was unresponsive to the RNA agonist (D).
(C–E) Data are mean values and standard deviations (error bars) of duplicates for each point.(the 14 residue linker would have to span 30 A˚, Figure 4D).
According to this model, there could be a contact between the
CTD in the region of residue 869 and a24 at the extremity of
the insertion domain. In addition, the only remaining poorly
ordered loop in the Hel2 domain (residues 667–673 lack electron
density) is in a suitable position to interact with and possibly
stabilize the critical RNA-binding loop containing Phe855,
mentioned above (observed residue 666 is very close to the
modeled position of CTD residue 851). Taken together, these
observations suggest that our model of the binding of 50ppp-
dsRNA to RIG-I is highly plausible.
The Autorepressed State
The structures of the full-length and DCTD dRIG-I suggest that
free RIG-I exists in an open state with the tandem CARDs
bound to the helicase insertion domain and with the CTD flex-
ibly linked to the helicase (Figure 4F). How does this conforma-
tion repress signaling? In early work, the ‘‘repressor/regulatory
domain’’ (RD) was identified as a region spanning residues
735–925 of hRIG-I with dominant-negative activity in signaling
and thus presumed to maintain RIG-I in an autorepressed state430 Cell 147, 423–435, October 14, 2011 ª2011 Elsevier Inc.(Saito et al., 2007). Subsequently, this construct was found to
poorly behave in vitro (which can now be understood because
residues 735–925 comprise strand b13 from Hel2, the bridging
domain, and the CTD), and the RD was redefined as the soluble
and well-folded triphosphate-binding CTD (residues 802–925
[Cui et al., 2008] or 792–925 [Takahasi et al., 2008]). The major
mechanism through which the isolated CTD inhibits RIG-I acti-
vation was found to be competition with native RIG-I for 50 ppp-
dsRNA binding (Cui et al., 2008). That the CTD is not directly
involved in autorepression is further supported by its lack of
binding to the helicase in vitro (Figure 5A). On the other hand,
considerable evidence favors a crucial role of the CARDs in
maintaining the nonsignaling, ligand-free state with concomi-
tant inhibition of the dsRNA-dependent ATPase activity, pre-
sumably by masking an RNA-binding site on the helicase
domain (Cui et al., 2008; Gee et al., 2008). These observations
are now rationalized by our structures of 1–794 and 1–933,
which both show binding of the CARDs to the Hel2i domain in
a way that partially overlaps with the dsRNA-binding site (Fig-
ure 4F). Indeed, if our model for the CTD position in the acti-
vated state is correct, then not only part of the bound dsRNA
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Figure 6. Schematic Diagram Showing
Structure-Based Model for RIG-I Activation
by Short 50ppp-dsRNA
RIG-I domains are colored consistently with other
figures. Dotted lines represent flexible linkers. The
50 and 30 strands of the dsRNA are colored red and
purple, respectively. See also Movie S3.
(A) Autorepressed state.
(B) Initial capturing of 50ppp-dsRNA by the CTD.
(C) Co-operative ATP and dsRNA binding to the
helicase leads to a conformational switch to a
closed form with high affinity for dsRNA. Con-
comitantly the CARDs are expelled. ATP hydro-
lysis could allow cycling between (C) and (D)
pending CARD ubiquitination.
(D) K63-linked polyubiquitination or polyubiquitin
binding of the CARDs allows downstream sig-
naling via MAVS.
(E) ATP hydrolysis leads to helicase reopening,
allowing recycling of RIG-I as long as the CARDs
no longer bind polyubiquitin.but also the entire CTD would clash with CARD2 (Figure 4F). In
support of this scenario, we show biochemically in vitro for
dRIG-I that the isolated CARDs, but not the isolated CTD, pull
down the helicase domain, and the CARDs-helicase interaction
is eliminated by either addition of dsRNA (which competes with
the CARDs for binding to the helicase) or use of the 1–794
construct (in which CARDs are already bound to the helicase
in cis) (Figure 5A). Furthermore, our model predicts that disrup-
tion of the binding of the CARDs to the Hel2i domain should
result in constitutively active RIG-I. Indeed, when the conserved
interface residue Phe540 in dRIG-I (Figure S4C) is substituted
by alanine or aspartic acid, mutated dRIG-I, despite being
poorly expressed, exhibits a constitutively active phenotype in
chicken DF-1 cells. This is revealed by a significant enhance-
ment of the expression of Mx1 (an IFN-induced gene in chicken)
over the wild-type (WT) dRIG-I background (Figures 5B, 5C, and
5E). Likewise, these dRIG-I mutants and their human counter-
parts F539A and F539D display constitutive activity in stimu-
lating the human IFN-b promoter in human Huh7.5 cells (in
which hRIG-I is disabled) despite very low expression of the
former (Figures 5B, 5D, and 5E). Notably, the F > D substitution
consistently confers a higher constitutive RIG-I activity than
F > A, despite systematically lower expression, presumably
because it is more effective in disrupting the CARD2-Hel2i
interface.Cell 147, 423–435,Structure-Based Functional Model
for RIG-I Activation by Short 50ppp-
dsRNA
Figure 6andMovieS3showour structure-
based model for RIG-I activation by short
(20–40 bp) blunt-end 50ppp-dsRNA. In
the ligand-free, autorepressed state, the
helicase is in an open and flexible state
with low affinity for ATP and dsRNA
(Figure 6A). In this state, binding of
CARD2 to the helicase insertion domain,
and possibly the presence of the longCARD2-helicase linker, sterically hinders not only dsRNA binding
to the helicase but also access of ubiquitination enzymes and
covalent or noncovalent binding of polyubiquitin, thus inhibiting
signaling via MAVS. In contrast, the CTD is flexibly linked to the
helicase without strong interactions with the rest of the protein.
Thus the CTD remains available for sensing and capturing
50ppp-dsRNA as the first step in activation of RIG-I thanks to its
significantly higher affinity (10-fold) and longer off-rate (327 s
compared to 28 s) for 50ppp-dsRNA compared to 50OH-dsRNA
(Lu et al., 2010) (Figure 6B). Initial, long-lifetime binding to the
CTD increases the local concentration of dsRNA in the vicinity
of the helicase, favoring the co-operative binding of ATP and
dsRNA and inducing the high ligand affinity, closed form of the
helicase. The associated conformational switch forces the
release of the tandem CARDs, the continued binding of which is
sterically incompatible with tight dsRNA binding to the helicase
and the repositioned CTD (Figure 6C). Release of the CARDs on
a 55 residue long, flexible linker makes them freely accessible
for K63-linked polyubiquitination or polyubiquitin binding (Fig-
ure 6D). However, the state depicted in Figure 6C will not have
a long lifetime as it is competent for ATP hydrolysis; thus until
polyubiquitination happens, cycling between states 6B and 6C
could occur without necessarily full disassociation of the RNA
but with consumption of ATP. After polyubiquitination, down-
stream signaling via MAVS can finally occur. Indeed, as long asOctober 14, 2011 ª2011 Elsevier Inc. 431
Table 1. Diffraction Data and Refinement Statistics
Helicase
(242–794) Helicase Se
Helicase-ds19-
ADP-AlF3-Mg DCTD (1–794) FL (1–933) CTD (806–933) CTD-ds14
Diffraction Data
Space group H3 H3 P41 C2 P41212 P21212 C2
Cell dimensions (A˚) a = 192.1
b = 192.1
c = 49.0
a = b = 90
g = 120
a = 191.9
b = 191.9
c = 47.1
a = b = 90
g = 120
a = 129.3
b = 129.3
c = 106.3
a = 315.0
b = 134.5
c = 102.3
b = 92.2
a = 163.3
b = 163.3
c = 152.7
a = 54.3
b = 75.6
c = 38.6
a = 216.0
b = 90.6
c = 63.0
b = 90.4
Solvent content (%) 55.5 53.6 58.2 58.9 48.5 53.8 61.5
Wavelength (A˚) 0.976 0.976 0.939 0.976 1.037 0.939 0.939
Resolution range of data
(last shell) (A˚)
50.0–3.0
(3.1–3.0)
50.0–3.2
(3.3–3.2)
50.0–3.7
(3.8–3.7)
50.0–3.4
(3.5–3.4)
50.0–3.7
(4.0–3.7)
50.0–1.45
(1.5–1.45)
50.0–4.0
(4.2–4.0)
Completeness (last shell) (%) 99.3 (99.8) 95.6 (55.6) 99.9 (100) 97.6 (99.7) 99.7 (99.4) 97.5 (88.1) 98.8 (94.0)
R-sym (last shell) 6.5 (70.6) 7.1 (67.0) 19.0 (96.6) 10.9 (86.6) 9.1 (85.8) 3.9 (23.4) 12.1 (80.5)
I/sI (last shell) 16.0 (1.8) 11.7 (1.7) 10.8 (2.4) 15.5 (2.1) 15.9 (2.7) 13.7 (3.2) 10.3 (1.9)
Refinement
No. of reflections used
in refinement: work (free)
12746 (646) — 17885 (940) 54462 (2904) 21432 (1160) 27882 (1494) 9821 (495)
R factor (last shell) 0.211 (0.342) — 0.193 (0.283) 0.239 (0.298) 0.218 (0.334) 0.173 (0.248) 0.204 (0.318)
R free (last shell) 0.297 (0.348) — 0.263 (0.395) 0.277 (0.343) 0.274 (0.384) 0.194 (0.259) 0.248 (0.313)
No. of nonhydrogen atoms: —
Protein 3878 8495 21709 10914 1100 3964
RNA — 1452 — — — 1182
Ligand — 64 — — 1 Zn, 2 glycerol 4 Zn
Waters — — — — 223 —
Mean B value (A˚2) 81.4 — 97.4 129.7 148.5 12.4 77.9
Ramachandran Plot
Favored regions 94.2 — 91.0 91.3 91.3 95.7 94.6
Allowed regions 98.7 — 99.4 98.6 99.1 100.0 99.6
Disallowed regions 1.3 — 0.6 1.4 0.9 0.0 0.4
Rmsds from ideal values
Bond distances (A˚) 0.005 — 0.007 0.007 0.007 0.009 0.006
Angles (o) 0.956 — 1.28 1.11 1.13 1.39 1.13the CARDs stay polyubiquitinated, for steric reasons they cannot
be rebound to the helicase to reconstitute the autorepressed
state even after ATP hydrolysis opens the helicase andpotentially
remainavailable for signalinguntil deubiquitinated (Figure 6E).We
emphasize that the above mechanism is for short (20–40 bp)
blunt-end 50ppp-dsRNA. However, RIG-I can also be activated
by long (>200 bp) dsRNAs without triphosphate ends (Binder
et al., 2011), although the existence of suchRNAs in infected cells
is controversial, particularly for negative-strand ssRNA viruses
(Gerlier and Lyles, 2011; Schlee et al., 2009). A possible explana-
tion is that RIG-I helicase domain might be capable of internal
binding on dsRNAwithout requiring a 50ppp blunt end but almost
certainly with much lower affinity because the CTD cannot be
engaged, and this may be sufficient to displace the CARDS.
Concluding Remarks
The crystal structures presented here allow us to propose a
detailed structure-basedmechanism for RIG-I activation consis-432 Cell 147, 423–435, October 14, 2011 ª2011 Elsevier Inc.tent with many prior observations. Indeed we show that RIG-I is
optimized to bind panhandle-like blunt-end 50ppp-dsRNA, the
currently accepted RIG-I MAMP, and in doing so releases the
CARDs for signaling. Furthermore, the structures provide rich
information that can be exploited to further refine our under-
standing of the RIG-I mechanism. A clear priority is to verify
by direct structure determination the model for 50ppp-dsRNA
binding to the combined helicase and CTD. Other outstanding
questions to be investigated include the structural basis for the
interaction of RIG-I with MAVS (Belgnaoui et al., 2011; Hou
et al., 2011) and clarification of the step(s) at which ATP hydro-
lysis is important and its consequences, together with (de)-
polyubiquitination for the duration of signaling competence
and recycling or degradation. Many of the structural features
described here will be common to the homologous RLHs,
MDA-5, and LGP2. The most striking sequence differences
between hMDA-5 and hRIG-I are the significantly longer linker
between CARD2 and the helicase (105 compared to 55 residues)
and, in the helicase insertion domain, the shortening of a22 and
a24 and the insertion of an acidic stretch between a25 and a26
(Data S2). These differences could affect the CARD interactions
with the helicase in the autorepressed state as well as the
competition with dsRNA for binding and might ultimately explain
the still obscure mechanistic differences between MDA-5 and
RIG-I. Beyond this, our RIG-I structures give insight into the
whole RIG-I-like dsRNA/DNA-binding subfamily of SF2 heli-
cases, including helicase containing Dicers. Finally these studies
further highlight and give insight into the diverse biological func-
tions of helicases (Linder and Jankowsky, 2011), revealing struc-
tural details showing how an innate immune pattern-recognition
receptor that is also a DECH helicase couples 50-triphosphory-
lated base-paired RNA and ATP binding to enable interferon
signaling.
EXPERIMENTAL PROCEDURES
Expression and Purification of RIG-I Constructs
Constructs comprising residues 1–933, 1–794, and 242–794 of Anas
platyrhynchos RIG-I (accession number ACA61272) were cloned from a
synthetic gene into pFastBAC and expressed in HiFive insect cells following
standard procedures. Protein extracted from lysed cells was purified on a
Nickel NTA column via a 6-histidine tag, which was then cleaved with TEV
protease. Cleaved protein was repurified on Nickel-NTA and by size-exclusion
chromatography. Seleno-methionine-labeled protein was produced in HiFive
cells adapted to ESF921 methionine-free medium. dRIG-I CTD (806–933) and
CARDs (1–210) were expressed in E. coli from a PET11 vector in BL21* cells.
Crystallization and Structure Determination
Protein crystals were grown in sitting or hanging drops by mixing protein and
reservoir solution in a 1:1 ratio. Crystallization conditions are given in the
Extended Experimental Procedures. Glycerol cryoprotected crystals were
flash frozen in liquid nitrogen and exposed on beamline ID14-4 at the European
Synchrotron Radiation Facility (ESRF), Grenoble, France. Diffraction data and
refinement statistics are given in Table 1. dRIG-I helicase structure was deter-
mined by the SAD method using seleno-methionine-labeled protein. Subse-
quent structures were determined by molecular replacement. dRIG-I CTD
was solved using zinc SAD.
Functional Analysis of dRIG-I and hRIG-I
The abilities of WT and F540/F539mutants of dRIG-I and hRIG-I to activate the
innate immune response were tested in chicken DF-1 (without endogenous
RIG-I) and/or human Huh7.5 cells (with endogenous inactive T55I hRIG-I
mutant). Cells seeded the day before were transfected with RIG-I expression
vectors supplemented or not with pcIFN-b-luc and followed 1 day later by
transfection of rabies leader as 50ppp-RNA agonist. The day after, the human
IFN-b promoter activation and chicken Mx1 gene transcription levels were
measured using a luciferase assay and RT-qPCR, respectively. RIG-I protein
expression was determined by western blot of cell extracts.
ACCESSION NUMBERS
The PDB accession codes for coordinates and structure factors are 4a2p
(dRIG-I helicase alone), 4a36 (dRIG-I helicase with 19-mer dsRNA and ADP-
AlF3), 4a2q (dRIG-I CARDs and helicase), 4a2w (full-length dRIG-I), 4a2v
(dRIG-I CTD), and 4a2x (dRIG-I CTD with 14-mer dsRNA).
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